Roche has initiated Phase I trials of intrathecal ASO against ApoE for early Alzheimer's disease. Why this is a revolution, who will benefit, and hidden risks. Read the analysis.
Stanford scientists have created an AI model for predicting Alzheimer's disease 10 years in advance based on brain microstructure with 92% accuracy. Learn about the breakthrough in diagnostics.
UCSF neural network predicts transition from MCI to Alzheimer's disease within 5 years with 94% accuracy using a single MRI. Alternative to PET and lumbar puncture. Details in the article.
Springer review confirms antioxidant and senolytic properties of cyanidin. Learn about its potential and the role of nanoparticles for crossing the BBB. Read more.
German scientists successfully tested nanobots for drug delivery across the BBB. The technology opens the way to treating Alzheimer's disease, but there are risks. Learn the details.
FDA approved Auvelity for the treatment of agitation in Alzheimer's disease. First non-antipsychotic agent without mortality risk. Learn about the new standard of therapy.
FDA extended review of subcutaneous Lecanemab for therapy initiation. Learn about the new standard of home Alzheimer's treatment and approval forecasts.
From the web
Alzheimer-Krankheit – Wikipedia
https://de.wikipedia.org/wiki/Alzheimer-Krankheit
Sie ist für 60 bis 70 Prozent aller Demenzerkrankungen verantwortlich. Von Alzheimer sind fast ausschließlich Menschen höheren …